Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Acta Haematologica · 2024
DOI: 10.1159/000542704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2024. Verfasst von Muhammad Faisal Aslam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ascension St. Vincent's East Hospital, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Advances in novel therapies have improved outcomes for multiple myeloma (MM) patients and the use of allo-SCT has decreased. Current guidelines no longer support allo-SCT as consolidation therapy for newly diagnosed MM, even in high-risk cases. Summary: Allo-SCT is now typically considered only within clinical trials for young, high-risk patients with relapsed or refractory MM (RRMM). It has not proven favorable despite its historical use. CAR T-cell therapy and bispecific antibodies have shown promise in treating triple- and penta-exposed/refractory MM, yet relapse remains common with poor survival rates. The efficacy of allo-SCT following BCMA-directed therapy and other new T-cell-directed therapies is unclear. Allo-SCT might be a viable option for eligible patients who relapse after these therapies, or where such options are unavailable. Advancements in reduced-intensity conditioning regimens have led to lower toxicity and transplant-related (TR) morbidity, lower graft-versus-host disease (GvHD), and TR mortality. Expanded use of alternative donors, like haploidentical donors, has yielded comparable outcomes. Better post-transplant GvHD regimens and maintenance strategies to prevent relapse have been developed. Key Messages: This review analyzes available literature to better understand the safety, efficacy, and current role of allo-SCT in managing MM. Newer regimens are needed as routine use of allo-SCT cannot be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Ascension St. Vincent's East Hospital, Birmingham, Alabama, USA.
- Department of Medicine/Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Medicine, Shifa International Hospital, Islamabad, Pakistan.
- Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
- Department of Medicine, The State University of New York at Buffalo-Catholic Health System, Buffalo, New York, USA.
- Department of Medicine, Lahore Medical and Dental College, Lahore, Pakistan.
Zitieren
APA
Aslam, M. F., Cheema, A. Y., Shahid, D., Maryam, B., Mukhopadhyay, D., Munir, M., Najam, A., Ali, H. M., Bashir, Q., & Anwer, F. (2024). Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Acta Haematologica. https://doi.org/10.1159/000542704
Vancouver
Aslam MF, Cheema AY, Shahid D, Maryam B, Mukhopadhyay D, Munir M, et al. Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Acta Haematologica. 2024. doi:10.1159/000542704
BibTeX
@article{Aslam2024,
author = {Aslam, Muhammad Faisal and Cheema, Asfand Yar and Shahid, Daniyal and Maryam, Bibi and Mukhopadhyay, Debduti and Munir, Mishaal and Najam, Ali and Ali, Hossam M and Bashir, Qaiser and Anwer, Faiz},
title = {Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000542704}
}
EUVIMED